Therapies for Myocardial Injury and Infarction
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".
Deadline for manuscript submissions: closed (20 December 2019) | Viewed by 102056
Special Issue Editor
Interests: myocardial infarction; coronary artery disease; atherosclerosis; magnetic resonance imaging; catheterization
Special Issue Information
Dear Colleagues,
Despite marked advances in the diagnosis and management of patients with myocardial infarction (MI), the burden of recurrent cardiovascular events, including mortality, remains high. Acute MI causes more than a third of deaths in developed nations annually. The one-year mortality of unselected patients with ST-segment elevation MI (STEMI) in national registries is around 10%.
The extent of myocardial loss after STEMI (infarct size) is one of the main determinants of post-MI mortality and morbidity, including heart failure. For this reason, experimental and clinical research is focused on potential therapies able to reduce MI size in conjunction with reperfusion. In addition to infarct size, several clinical and preclinical studies have shown that the presence and extent of microvascular obstruction (MVO) represents an important independent predictor of adverse LV remodeling, and recent evidence support the notion that MVO may be more predictive of major adverse cardiovascular events than infarct size itself. Currently, no effective therapies for reducing infarct size or MVO have been translated into improved clinical outcomes, despite tremendous research efforts in this field. This has been suggested to be a consequence of clinical cardioprotection studies performed without robust preclinical data or with a weak study design in terms of patient selection and/or inappropriate timing and mode of delivery of the cardioprotective agent. Moreover, previous cardioprotection studies, mainly aimed at protecting cardiomyocytes and reducing infarct size, neglected other targets for cardioprotection, in particular coronary microcirculation. On the contrary, infarct size and coronary MVO represent two complementary therapeutic targets that should be simultaneously pursued in order to overcome the limitations of previous cardioprotective clinical studies.
Against this background, a panel of international experts with vast expertise in post-MI pathophysiology, cardioprotection, and reperfusion injury will provide new lines of evidence of optimized treatment of myocardial infarction with the main focus to target myocardial injury and coronary microvascular obstruction as the primary treatment goal in myocardial infarction to further improve prognosis. The resulting Special Issue titled “Therapies for Myocardial Injury and Infarction” including original and review articles summarizes the current evidence of myocardial injury including MVO during STEMI and will cover all important aspects from diagnosis, imaging, and treatment up to effectively translating cardioprotective strategies into improved clinical outcomes for infarction patients. All suggested authors have performed numerous trials particularly focusing on cardioprotection and reperfusion injury in order to improve prognosis in STEMI survivors.
Prof. Dr. Ingo Eitel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Myocardial infarction
- Myocardial injury
- Reperfusion injury
- Cardioprotection
- Microvascular obstruction
- Infarct size
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.